Spyre Therapeutics CFO sells 25,000 shares
The option award represents a right to purchase 404,857 shares, with vesting subject to continued employment.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Spyre Therapeutics, Inc. (SYRE) Chief Financial Officer Scott L. Burrows exercised options for 17,500 shares on September 30, 2026, at a $14.50 exercise price, then sold 17,500 common shares at a weighted-average $89.89 per share; prices ranged from $89.00 to $90.62. On October 1, he exercised options for 7,500 shares at $14.50 and reported five sales: 600 shares at a weighted-average $89.07 ($88.63–$89.53 range), 1,500 at $90.27 ($89.96–$90.95), 2,100 at $91.92 ($91.41–$92.26), 3,071 at $92.95 ($92.54–$93.53), and 229 at $93.57 ($93.54–$93.59). Across both dates, his reported sales covered 25,000 shares. The October 1 transactions were pursuant to a Rule 10b5-1 trading plan adopted November 10, 2025. A post-transaction amount includes 33,738 RSUs, each a contingent right to one common share upon vesting; they vest September 1, 2027, subject to continued employment.
Insider Trade Summary 10b5-1
Exercise and Sale: 25,000 shares ($1.90M approx. pre-tax spread)
Exercise and Sale
10 txns
Insider
Burrows Scott L
Role
Chief Financial Officer
Sold
25,000 shs ($2.26M)
Approx. gross sale proceeds
$2.26M
Approx. exercise cost
$363K
Approx. pre-tax spread
$1.90M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F2, F9 | 7,500 | $0.00 | $0.00 |
| Exercise | Common Stock F2 | 7,500 | $14.50 | $109K |
| Sale | Common Stock F2, F3 | 600 | $89.07 | $53K |
| Sale | Common Stock F2, F4 | 1,500 | $90.27 | $135K |
| Sale | Common Stock F2, F5 | 2,100 | $91.92 | $193K |
| Sale | Common Stock F2, F6 | 3,071 | $92.95 | $285K |
| Sale | Common Stock F2, F7, F8 | 229 | $93.57 | $21K |
| Exercise | Stock Option (Right to Buy) F9 | 17,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 17,500 | $14.50 | $254K |
| Sale | Common Stock F1 | 17,500 | $89.89 | $1.57M |
Holdings After Transaction:
Stock Option (Right to Buy) — 312,357 contracts (Direct);
Common Stock — 79,762 shares (Direct)
Footnotes (9)
- F1. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.00 to $90.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- F2. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
- F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.41 to $92.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.54 to $93.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F7. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.54 to $93.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F8. Includes 33,738 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of the Issuer's common stock. The RSUs vest on September 1, 2027, subject to the Reporting Person's continued employment with the Issuer.
- F9. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Key Figures
Shares sold: 25,000 shares
Options exercised: 17,500 shares
Options exercised: 7,500 shares
+4 more
7 metrics
Shares sold
25,000 shares
Across September 30 and October 1, 2026
Options exercised
17,500 shares
September 30, 2026
Options exercised
7,500 shares
October 1, 2026
Exercise price
$14.50 per share
Options exercised on September 30 and October 1, 2026
Weighted-average sale price
$89.89 per share
September 30 sale of 17,500 shares
RSUs
33,738 RSUs
Vesting September 1, 2027, subject to continued employment
Shares covered by option right
404,857 shares
Option described in the footnote
Key Terms
Rule 10b5-1 trading plan, weighted average price, RSUs, reverse stock split
4 terms
Rule 10b5-1 trading plan regulatory
"pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
RSUs financial
"Includes 33,738 RSUs"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
reverse stock split financial
"1-for-25 reverse stock split on September 8, 2023"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were the prices for Scott L. Burrows's October 1 SYRE sales?
The five reported blocks were 600 shares at a weighted-average $89.07 per share, 1,500 at $90.27, 2,100 at $91.92, 3,071 at $92.95, and 229 at $93.57. Their respective price ranges were $88.63–$89.53, $89.96–$90.95, $91.41–$92.26, $92.54–$93.53, and $93.54–$93.59.
What vesting schedule applied to the option reported by SYRE CFO Scott L. Burrows?
The option described a right to purchase 404,857 shares, adjusted for the issuer's 1-for-25 reverse stock split on September 8, 2023. One quarter vested and became exercisable on September 1, 2024; the remaining three quarters vest in monthly installments over the following three years, subject to continued employment.
AI-generated analysis. How Rhea-AI works. Not financial advice.
